|1.||Lilja, Hans: 5 articles (02/2013 - 07/2007)|
|2.||Vickers, Andrew J: 3 articles (02/2013 - 07/2007)|
|3.||Valtonen-André, Camilla: 3 articles (02/2013 - 08/2010)|
|4.||Klein, Robert J: 3 articles (10/2010 - 05/2010)|
|5.||Waters, Kevin M: 2 articles (02/2013 - 10/2010)|
|6.||Stram, Daniel O: 2 articles (02/2013 - 10/2010)|
|7.||Henderson, Brian E: 2 articles (02/2013 - 10/2010)|
|8.||Kolonel, Laurence N: 2 articles (02/2013 - 10/2010)|
|9.||Haiman, Christopher A: 2 articles (02/2013 - 10/2010)|
|10.||Halldén, Christer: 2 articles (08/2010 - 05/2010)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/01/1998 - "Previous studies have shown that beta-microseminoprotein (beta-MSP) may be used as a diagnostic marker for prostate cancer. "
02/06/2013 - "Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations."
10/01/2010 - "A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations."
01/19/2010 - "MSMB, a gene coding for beta-microseminoprotein, has been identified as a candidate susceptibility gene for prostate cancer (PrCa) in two genome-wide association studies (GWAS). "
05/12/2009 - "Two recent genome-wide association studies have independently identified a prostate cancer susceptibility locus on chromosome 10q11.2. The most significant single-nucleotide polymorphism (SNP) marker reported, rs10993994, is 57 bp centromeric of the first exon of the MSMB gene, which encodes beta-microseminoprotein (prostatic secretory protein 94). "
11/01/1996 - "Immunoglobulin binding factor (IgBF) produced in the prostate is a useful marker for the diagnosis of prostatic tumor. "
01/01/1994 - "Immunoglobulin binding factor: a new tumor marker for prostatic tumors."
04/01/2008 - "A number of genes identified have been shown to be associated with prostate disease and cancer, including beta-microseminoprotein (Msp) and tumor necrosis factor receptor superfamily 6 (Fadd). "
09/01/1989 - "beta-Microseminoprotein may be as useful as gamma-seminoprotein in the pathologic examination of prostatic diseases, especially in histogenic classification of tumors or metastatic tumors. "
01/01/1993 - "Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma."
12/01/1988 - "Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate."
12/01/1988 - "The levels of immunoreactive prostatic inhibin-like peptide (PIP), having follicle-stimulating hormone suppressing properties, were estimated in the sera and urine samples of patients with benign prostatic hyperplasia (BPH) and prostatic carcinoma (PC) as compared to age-matched controls. "
07/16/1993 - "A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines."
|5.||Endometrial Neoplasms (Endometrial Cancer)
05/01/2000 - "Prostatic secretory protein (PSP94) expression in human female reproductive tissues, breast and in endometrial cancer cell lines."
03/01/2008 - "Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer. "
|1.||Prostate-Specific Antigen (Semenogelase)
|2.||Messenger RNA (mRNA)
|5.||Prostatic Secretory Proteins
|6.||Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
|7.||Staphylococcal Protein A (A, Protein)
|8.||Fc Receptors (Fc Receptor)